FindTrial
Sign In

Demcizumab

DRUG6 trials

Sponsors

OncoMed Pharmaceuticals, Inc.

Conditions

Locally Advanced or Metastatic Solid TumorsNon Small Cell Lung CancerNonsquamous Nonsmall Cell Neoplasm of LungPancreatic CancerPrimary Peritoneal Carcinoma

Phase 1

A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer
CompletedNCT01189929
OncoMed Pharmaceuticals, Inc.Pancreatic Cancer
Start: 2010-08-31End: 2016-12-31Updated: 2020-09-09
A Study of Carboplatin and Pemetrexed Plus Demcizumab (OMP-21M18) in Subjects With Non-Squamous Non-Small Cell Lung Cancer
CompletedNCT01189968
OncoMed Pharmaceuticals, Inc.Non Small Cell Lung Cancer
Start: 2010-09-30End: 2016-09-30Target: 50Updated: 2020-09-09
A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian
TerminatedNCT01952249
OncoMed Pharmaceuticals, Inc.Primary Peritoneal Carcinoma
Start: 2013-08-05End: 2016-07-12Updated: 2020-09-09
A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid Tumors
CompletedNCT02722954
OncoMed Pharmaceuticals, Inc.Locally Advanced or Metastatic Solid Tumors
Start: 2016-01-31End: 2017-05-19Updated: 2020-08-11

Phase 2

A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer
CompletedNCT02259582
OncoMed Pharmaceuticals, Inc.Nonsquamous Nonsmall Cell Neoplasm of Lung
Start: 2015-02-28End: 2017-04-07Updated: 2020-09-09
Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma
CompletedNCT02289898
OncoMed Pharmaceuticals, Inc.Pancreatic Cancer
Start: 2015-04-20End: 2017-09-30Updated: 2020-09-28

Related Papers

Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC.
2018-02-0160 citations
A phase 1b study of the anti-cancer stem cell agent demcizumab (DEM), pemetrexed (PEM) &amp; carboplatin (CARBO) in patients (pts)with 1<sup>st</sup> line non-squamous NSCLC.
Journal of Clinical Oncology2016-05-202 citations
A phase 1b study of the anti-cancer stem cell agent demcizumab (DEM) and gemcitabine (GEM) +/- nab-paclitaxel in patients with pancreatic cancer.
Journal of Clinical Oncology2016-02-0114 citations
A phase Ib study of the anti-cancer stem cell agent demcizumab (DEM) &amp; gemcitabine (GEM) +/- paclitaxel protein bound particles (nab-paclitaxel) in pts with pancreatic cancer.
Journal of Clinical Oncology2015-05-2010 citations
A phase 1b study of the anti-cancer stem cell agent demcizumab (DEM), pemetrexed (PEM) &amp; carboplatin (CARBO) in pts with 1<sup>st</sup> line non-squamous NSCLC.
Journal of Clinical Oncology2015-05-201 citations
A phase 1b study of the anticancer stem cell agent demcizumab (DEM), pemetrexed (PEM), and carboplatin (CARBO) in pts with first-line nonsquamous NSCLC.
Journal of Clinical Oncology2014-05-206 citations
A phase 1b study of the anticancer stem cell agent demcizumab (DEM) and gemcitabine (GEM) with or without paclitaxel protein bound particles (nab-paclitaxel) in patients with pancreatic cancer.
Journal of Clinical Oncology2014-01-207 citations